BioXcel Therapeutics, Inc. Proceeds from Long-Term Debt Issued
BioXcel Therapeutics, Inc. (BTAI) reported Proceeds from Long-Term Debt Issued of $98.60 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-22.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2024-03-22
- BioXcel Therapeutics, Inc. proceeds from issuance of long-term debt for the quarter ending 2022-12-31 was $0.00.
- BioXcel Therapeutics, Inc. proceeds from issuance of long-term debt for the quarter ending 2022-09-30 was $30.00M.
- BioXcel Therapeutics, Inc. proceeds from issuance of long-term debt for fiscal 2022 was $98.60M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $30.00M derived: sum of 2 quarters · filed 2024-03-22 | $98.60M 10-K · filed 2024-03-22 | |
| 2022-09-30 | $30.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $98.60M 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $68.60M 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |